Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI method aims to sharpen prostate cancer treatment for patients with hip replacements

NCT ID NCT07042256

Symptom relief Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at whether a special low-field MRI scanner can give clearer images for prostate cancer radiation therapy in people who have both hips replaced. Standard MRI often creates blurry images around metal implants, making it hard to aim the radiation precisely. The researchers will test a system where patients are scanned in a low-field MRI and then moved to a radiation machine without changing position, hoping to improve treatment accuracy and reduce side effects. About 13 adults with localized prostate cancer and bilateral hip prostheses will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 13 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of localized prostate cancer suitable for definitive SBRT based on a multidisciplinary tumour board recommendation and / or clinical practice guideline. * Presence of bilateral hip prostheses labeled as MR safe or MR-conditional. * ECOG performance status ≤ 2. * Signed informed consent. * Age ≥18 years - Exclusion Criteria: * Large body size that would not fit into the MRI-simulator bore * Hip prosthesis that are labeled as MR unsafe; * Contraindications to MRI including but not limited to: * Claustrophobia unmanageable by sedation * Electronic devices such as pacemakers, defibrillators, deep brain stimulators, cochlear implants that are labeled as MR unsafe, electronic devices labeled as MR safe or MR conditional are not a contraindication; * Metallic foreign body in the eye or aneurysm clips in the brain; * Clinically significant concomitant diseases that would interfere with the study (e.g. hepatic dysfunction, cardiovascular disease). * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * Enrolment of the investigator, his/her family members, employees and other dependent persons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Localized prostate adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Zurich, Department of Radio-Oncology

    RECRUITING

    Zurich, Canton of Zurich, 8090, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.